NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Epidemiological Characteristics of COVID-19 in Patients With MS or NMO

CompletedN/A

Sponsor: Assistance Publique - Hôpitaux de Paris

Conditions: Multiple Sclerosis, NMO Spectrum Disorder, COVID-19

Interventions: Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)

Countries: France

The purpose of this study is to collect French medical data for patients with Multiple Sclerosis (MS) or NeuroMyelitis Optica (NMO) spectrum disorder who are diagnosed or strongly suspected of being infected with Covid19. The objective of this study is to provide scientific information regarding the possible risk factors in these patients, as a large part of them receive immunomodulatory or immunosuppressive treatments. The main objective of this study is thus to determine the epidemiological (eg, age, form of disease, disability) and pharmacological (related to immunomodulatory or immunosuppressive treatments) factors favoring the occurrence of a severe form of Covid-19 in MS and NMO patients.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria

* Patient with MS or NMO
* at least one of the following four criteria:

  * COVID + biologically confirmed
  * Typical ground glass opacity on thoracic CT-scan in epidemic areas
  * Anosmia or ageusia of sudden onset in the absence of rhinitis or nasal obstruction
  * Typical symptoms (triad associating cough, fever, asthenia) in epidemic zone
* Non opposition of the patient to the use of these data or non opposition of the confidential counselor / parent / relative (if the patient is unable to give his non-opposition, with collection as soon as possible of the non opposition of the patient) or non opposition of the 2 holders of parental authority (for minor patients)

Non-inclusion criteria

\- Patient under guardianship or safety measure

Locations (1)

Paris, France